<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01706120</url>
  </required_header>
  <id_info>
    <org_study_id>MITO-16 - MANGO-OV2</org_study_id>
    <secondary_id>2012-003043-29</secondary_id>
    <nct_id>NCT01706120</nct_id>
  </id_info>
  <brief_title>Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab</brief_title>
  <acronym>MITO16/MANGO-2</acronym>
  <official_title>A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of bevacizumab to first-line chemotherapy has been shown to improve progression
      free survival for patients with ovarian cancer. The purpose of this study is to explore the
      potential role of clinical and biologic factors in identifying those patients who benefit
      most from this combined therapy in terms of progression free and overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MITO-16 - MANGO-OV2 is a single-arm, open-label, non-comparative, multicenter, phase IV
      study. Patients will receive a combination of bevacizumab, paclitaxel and carboplatin as
      first line treatment (in-label dose and scheduling). This is an exploratory study attempting
      to identify potential prognostic clinical factors(such as hypertension) and prognostic
      biologic factors. Overall, 2 types of biomarkers are considered. Dynamic biomarkers are those
      expressing the changing nature of the disease in relation to the treatment or simply the
      tumour progression, these are typically not inherited. Genetic biomarkers are typically
      inherited and are expression of some characteristics potentially able to interfere with the
      treatment effect (i.e. Pharmacogenomics).

      The safety of this regimen in routine clinical practice will also be described.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>expression of soluble and tissutal biomarkers</measure>
    <time_frame>measured at baseline, at completion of chemotherapy, at disease progression or bevacizumab completion up to 15 monthsfor each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>evaluated every 3 weeks up to 15 month</time_frame>
    <description>according to Common Toxicity Criteria for Adverse Events v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients taking oral antidiabetic therapy</measure>
    <time_frame>at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients taking antithrombotic therapy</measure>
    <time_frame>at baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>First-line chemotherapy with bevacizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles
Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles
Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles</description>
    <arm_group_label>First-line chemotherapy with bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles</description>
    <arm_group_label>First-line chemotherapy with bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles</description>
    <arm_group_label>First-line chemotherapy with bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients ≥18 years of age.

          -  Patients with histologically confirmed epithelial ovarian carcinoma, fallopian tube
             carcinoma or primary peritoneal carcinoma, including mixed Mullerian Tumours Or
             Recurrent early stage epithelial ovarian or fallopian tube carcinoma treated with
             surgery alone.

          -  FIGO stage IIIB &amp; C or IV

          -  ECOG Performance Status of 0-2.

          -  Life expectancy of at least 12 weeks.

          -  Signed informed consent obtained prior to initiation of any study-specific procedures
             and treatment as confirmation of the patient's awareness and willingness to comply
             with the study requirements.

          -  Availability of tumour samples for molecular analyses

        Exclusion Criteria:

        Cancer related

          -  Ovarian tumours with low malignant potential (i.e. borderline tumours)

          -  Previous systemic anti-cancer therapy for advanced ovarian cancer.

          -  History or evidence of brain metastases or spinal cord compression.

          -  History or evidence of synchronous primary endometrial carcinoma, unless all of the
             following criteria related to the endometrial carcinoma are met:

               -  stage ≤Ia

               -  no more than superficial myometrial invasion

               -  no lymphovascular invasion

               -  not poorly differentiated (grade 3 or papillary serous or clear cell carcinoma).

          -  Other malignancy within the last 5 years, except for adequately treated carcinoma in
             situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited
             basal cell skin cancer.

        Other-treatment related

          -  Any prior radiotherapy to the pelvis or abdomen.

          -  Surgery (including open biopsy) within 4 weeks prior to the first bevacizumab dose or
             planned (In this case the patient can be enrolled but the administration of
             bevacizumab should be omitted at first cycle).

          -  Current or recent (within 10 days prior to the first study drug dose) use of full-dose
             oral or parenteral anticoagulant or thrombolytic agent for therapeutic purposes
             (except for central venous access patency, in which case international normalized
             ratio [INR] must be maintained below 1.5). Post operative prophylaxis with low
             molecular weight heparin sc is allowed.

          -  Current or recent (within 30 days of first study dosing) treatment with another
             investigational drug.

        Laboratory related

          -  Inadequate bone marrow function: ANC: &lt;1.5 x 109/l, or platelet count &lt;100 x 109/l or
             Haemoglobin &lt;9 g/dl. Patients may be transfused to maintain haemoglobin values ≥9
             g/dl.

          -  Inadequate coagulation parameters:

               -  activated partial thromboplastin time (APTT) &gt;1.5 xULN or

               -  INR &gt;1.5

          -  Inadequate liver function, defined as:

               -  serum (total) bilirubin &gt;1.5 x the upper limit of normal (ULN) for the
                  institution

               -  AST/SGOT or ALT/SGPT &gt;2.5 x ULN.

          -  Inadequate renal function, defined as serum creatinine &gt;2.0 mg/dl or &gt;177 micromol/l

          -  Proteinuria &gt;1g in a 24-hour urine collection (to be performed only among patients who
             showed a ≥3+ at urine dipstick).

        Patient related

          -  Pregnant or lactating patients.

          -  History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular
             accident (CVA) / stroke or transient ischemic attack (TIA) or sub-arachnoid
             haemorrhage within ≤6 months prior to the first study treatment).

          -  Uncontrolled hypertension (sustained systolic &gt;150 mm Hg and/or diastolic &gt;100 mm Hg
             despite antihypertensive therapy) or clinically significant (i.e. active)
             cardiovascular disease, including:

               -  myocardial infarction or unstable angina within ≤6 months prior to the first
                  study treatment

               -  New York Heart Association (NYHA) grade II or greater congestive heart failure
                  (CHF)

               -  serious cardiac arrhythmia requiring medication (with the exception of atrial
                  fibrillation or paroxysmal supraventricular tachycardia)

               -  peripheral vascular disease ≥grade 3 (i.e. symptomatic and interfering with
                  activities of daily living requiring repair or revision).

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to the first study treatment.

          -  Non-healing wound, ulcer or bone fracture. Patients with granulating incisions healing
             by secondary intention with no evidence of fascial dehiscence or infection are
             eligible but require three weekly wound examinations.

          -  Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer,
             etc.), physical examination or laboratory findings that may interfere with the planned
             treatment, affect patient compliance or place the patient at high risk from
             treatment-related complications.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicoletta Colombo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gennaro Daniele, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roldano Fossati, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mario Negri Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Floriani, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mario Negri Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.S.O. SS Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili - Università di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ramazzini di Carpi /Ospedale di Mirandola</name>
      <address>
        <city>Carpi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Garibaldi Nesimadi Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cannizzaro</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Faenza</name>
      <address>
        <city>Faenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Fano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Arcispedale Sant'Anna di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fabrizio Spaziani di Frosinone / Osp. SS Trinità di Sora</name>
      <address>
        <city>Frosinone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.O. Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Martino IST</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Guastalla</name>
      <address>
        <city>Guastalla</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A. Manzoni</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Manerbio</name>
      <address>
        <city>Manerbio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. C. Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>MIlano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.L.S.S. 13</name>
      <address>
        <city>Mirano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Sacro Cuore Don Calabria</name>
      <address>
        <city>Negrar</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Silvestrini</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria degli Angeli</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi / Ospedale Civile</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Calibita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. OIRM-S. Anna</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASS N 1 Triestina</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. di Udine S. Maria delle Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale del Ponte</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prognostic factors</keyword>
  <keyword>biologic factors</keyword>
  <keyword>clinical factors</keyword>
  <keyword>routine clinical practice</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

